eBook: Accelerate and optimise preclinical research programmes
Posted in News
|According to a 2020 Biotechnology Innovation Organization report, fewer than 8% of drug candidates that enter clinical trials eventually receive regulatory approval. One of the primary reasons for this high failure rate is the poor translatability of preclinical findings, often due to a lack of appropriate mouse models.
This guide explores key considerations for generating and managing genetically engineered mouse models (GEMs) to accelerate and optimise preclinical research programmes.
- Generating GEMs: three cutting-edge technologies you need to know.
- Five key components of effective colony management.
- How integrated solutions can unlock the full potential of preclinical research.
